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RESEARCH ARTICLE
(CCUG)n RNA toxicity in a Drosophila model of myotonic
dystrophy type 2 (DM2) activates apoptosis
Vildan Betul Yenigun1,2,3,*,‡, Mario Sirito2,‡, Alla Amcheslavky4,‡, Tomek Czernuszewicz2,
Jordi Colonques-Bellmunt5, Irma Garcıá-Alcover5, Marzena Wojciechowska2, Clare Bolduc1,
Zhihong Chen1, Arturo López Castel5, Ralf Krahe2,3,6,§ and Andreas Bergmann1,3,4,§
ABSTRACT
The myotonic dystrophies are prototypic toxic RNA gain-of-function
diseases. Myotonic dystrophy type 1 (DM1) and type 2 (DM2)
are caused by different unstable, noncoding microsatellite
repeat expansions – (CTG)DM1 in DMPK and (CCTG)DM2 in CNBP.
Although transcription ofmutant repeats into (CUG)DM1 or (CCUG)DM2
appears to be necessary and sufficient to cause disease, their
pathomechanisms remain incompletely understood. To study the
mechanisms of (CCUG)DM2 toxicity and develop a convenient model
for drug screening, we generated a transgenic DM2 model in the fruit
fly Drosophila melanogaster with (CCUG)n repeats of variable
length (n=16 and 106). Expression of noncoding (CCUG)106, but not
(CCUG)16, inmuscleand retinal cells led to the formationof ribonuclear
foci andmis-splicing of genes implicated inDMpathology.Mis-splicing
could be rescued by co-expression of human MBNL1, but not by
CUGBP1 (CELF1) complementation. Flies with (CCUG)106 displayed
strong disruption of external eye morphology and of the underlying
retina. Furthermore, expression of (CCUG)106 in developing retinae
caused a strong apoptotic response. Inhibition of apoptosis rescued
the retinaldisruption in (CCUG)106 flies.Finally,we tested twochemical
compounds that have shown therapeutic potential in DM1 models.
Whereas treatment of (CCUG)106 flies with pentamidine had no effect,
treatment with a PKR inhibitor blocked both the formation of RNA foci
and apoptosis in retinae of (CCUG)106 flies. Our data indicate that
expression of expanded (CCUG)DM2 repeats is toxic, causing
inappropriate cell death in affected fly eyes. Our Drosophila DM2
model might provide a convenient tool for in vivo drug screening.
KEY WORDS: Myotonic dystrophy, DM2, RNA toxicity, Drosophila,
Muscleblind, Apoptosis
INTRODUCTION
Myotonic dystrophy (DM) is the most common adult-onset
neuromuscular disorder (Harper, 2001). DM is characterized by
myotonia, muscle weakness and wasting, as well as multi-systemic
manifestations, including insulin resistance, gonadal atrophy,
cataracts and neuropsychiatric symptoms (La Spada and Taylor,
2010; Udd and Krahe, 2012; Thornton, 2014). There are two
genetically distinct types, DM1 and DM2, which are caused by
similar noncoding repeat expansions in different genes: a (CTG)n
expansion in the 3′UTR of the DM1 protein kinase (DMPK) gene in
DM1; and a (CCTG)n expansion in the first intron of the CCHC-type
zinc finger nucleic acid binding protein (CNBP) gene [also known as
zinc finger protein 9 (ZNF9)] in DM2 (La Spada and Taylor, 2010;
Udd and Krahe, 2012; Timchenko, 2013; Thornton, 2014). Whereas
expansion size generally correlates with disease severity in DM1 and
is the basis for the observed pronounced anticipation, there does not
appear to be a genotype/phenotype correlation in DM2 (Udd and
Krahe, 2012). DM2 expansions up to 44 kb (11,000 CCTG) have
been reported (Liquori et al., 2001; Day et al., 2003; Sallinen et al.,
2004); the smallest expansions associated with clinically detectable
manifestations are between 55 and 100 CCTG repeats (Liquori et al.,
2001; Lucchiari et al., 2008; Bachinski et al., 2009).
The prevailing paradigm is that both DM1 and DM2 are toxic
RNA-mediated spliceopathies, mediated by the mutant expansions of
normally polymorphic (CTG)n or (CCTG)n repeats: transcription into
(CUG)DM1 or (CCUG)DM2 RNA is necessary and sufficient to cause
disease (Osborne and Thornton, 2006; Klein et al., 2011; Sicot and
Gomes-Pereira, 2013). Mutant RNAs accumulate in ribonuclear foci
and interfere with RNA splicing, transcription and/or translation of
downstream effector genes, resulting in the characteristic pleiotropic
phenotype (Schoser and Timchenko, 2010; Jones et al., 2011; Sicot
et al., 2011; Udd and Krahe, 2012; Timchenko, 2013).
Mechanistically, (CUG)DM1 or (CCUG)DM2 RNA foci sequester
Muscleblind-like (MBNL) proteins, which are zinc-finger RNA-
binding proteins involved in alternative RNA splicing (Miller et al.,
2000; Mankodi et al., 2001, 2003; Kanadia et al., 2003; Pascual
et al., 2006; Lee and Cooper, 2009; Schoser and Timchenko, 2010;
Jones et al., 2011; Meola et al., 2013). MBNL proteins are highly
conserved from flies to humans. The fruit fly Drosophila
melanogaster has a single MBNL gene, muscleblind (mbl), which
is involved in muscle development and photoreceptor neuron
differentiation in the eye (Begemann et al., 1997; Artero et al., 1998;
Pascual et al., 2006). Loss of mbl causes muscle defects and
blindness, hence the name of the gene (Begemann et al., 1997;
Artero et al., 1998). Similarly, in DM1 and DM2 patients [humans
have three MBNL homologous genes: MBNL1-3 (Fardaei et al.,
2002)], the sequestration of MBNL proteins in RNA foci reduces
the amount of functional MBNL proteins available for proper
splicing, resulting in a shift from the normal adult splice pattern toReceived 11 May 2016; Accepted 14 June 2017
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an inappropriate embryonic/fetal pattern of target transcripts (Miller
et al., 2000; Mankodi et al., 2001; Jiang et al., 2004; Kanadia et al.,
2006; Holt et al., 2009).
More than 20 transcripts have been shown to be mis-spliced in
DM (Jiang et al., 2004; Gatchel and Zoghbi, 2005; Botta et al.,
2007; Du et al., 2010). For example, aberrant splicing of the muscle-
specific chloride channel CLCN1 and the insulin receptor (INSR)
accounts for myotonia in DM (Savkur et al., 2001, 2004; Mankodi
et al., 2002; Wheeler et al., 2007; Tonevitsky and Trushkin, 2009;
Tang et al., 2012; Santoro et al., 2013). Other mis-spliced genes in
DM include the muscle contractile proteins cardiac troponin
(TNNT2) and skeletal muscle troponin (TNNT3) (Philips et al.,
1998; Yuan et al., 2007; Vihola et al., 2010).
In addition to the MBNL family of proteins, at least two other
RNA-binding proteins have been implicated in DM1. Expanded CUG
repeats increase the activities of CUG-binding protein (CUGBP1; also
known as CELF1) and dsRNA-dependent protein kinase (PKR; also
known as EIF2AK2) (Tian et al., 2000; Timchenko et al., 2001a,b;
Mankodi et al., 2003; Ward et al., 2010; Jones et al., 2011). Whether
these factors are involved in DM2 is unclear.
There is currently no cure for DM. Most efforts to identify
therapeutic modes of intervention are focused on the reversal of RNA
toxicity. To develop a convenient model for drug screening, we
generated a DM2model in the fruit flyDrosophila melanogaster. We
obtained transgenes that express noncoding transcripts of variable
size, with the largest at 106 CCUG repeats (DM2-106). Transgenic
DM2-106 flies recapitulate many features observed in the human
disease condition. They form RNA foci in muscles and retinal cells
and affect RNA splicing of splicing reporter genes. Although we did
not observe muscle atrophy in DM2-106 flies, they displayed strong
disruption in the external morphology of the eye and underlying
retina. Expression of MBNL1, but not CUGBP1, was able to rescue
the eye phenotype of DM2-106 flies. Furthermore, DM2-106 flies
exhibited a strong apoptotic response in developing retinae, and
inhibition of apoptosis rescued the retinal disruption. Finally, we
tested two chemical compounds with therapeutic potential in DM1.
Whereas treatment ofDM2-106 flies with pentamidine had no effect,
treatment with a PKR inhibitor blocked both the formation of RNA
foci and apoptosis in retinae of DM2-106 flies. These data suggest
that the Drosophila DM2 model described here may provide a
suitable tool for drug screening.
RESULTS
Transcripts with expanded (CCUG)n repeats form RNA foci
The smallest reported DM2 expansions associated with clinically
detectable manifestations are between 55 and 100 CCTG repeats
(Liquori et al., 2001; Lucchiari et al., 2008; Bachinski et al., 2009).
To generate a DM2 model in Drosophila, we prepared two
transgenes: a control transgene expressing a noncoding transcript
with 16 CCUG repeats in the normal range (referred to as N-16), and
an experimental transgene expressing a noncoding RNA with 106
CCUG repeats (DM2-106) (Fig. 1A). Because the (CCTG)DM2
expansion is part of a complex polymorphic motif (Bachinski et al.,
2003, 2009) of the form (TG)n(TCTG)n(CCTG)>26 and the
(TG)n(TCTG)n polymorphic repeats have been shown to affect
DNA structure (Edwards et al., 2009), we included a (TG)n(TCTG)n
tract in our (CCTG)DM2 constructs. Both control and DM2 transgenes
contained the polymorphic (TG)n(TCTG)n repeats upstream of the
(CCTG)n tract: the N-16 allele had a (TG)20(TCTG)12(CCTG)16
motif, while the DM2-106 allele had a (TG)22(TCTG)2(CCTG)106
motif (Fig. 1A). These transgenes are under the control of a UAS
promoter (Brand and Perrimon, 1993) and expression can be induced
using convenient Gal4 drivers, such as muscle-specific Mhc-Gal4
and eye-specific GMR-Gal4.
Because myotonia and muscle wasting are associated with human
DM2, we first expressed the control and disease transgenes using
Mhc-Gal4 and analyzed the morphology of the indirect flight muscle
(IFM). As nuclear retention of RNA-protein aggregates (foci) is a
hallmark of DM2 (Mankodi et al., 2003; Jones et al., 2011; Udd and
Krahe, 2012; Meola et al., 2013), we first determined that DM2-106
flies mirror this disease-linked trait and performed FISH analysis to
detect foci in the nucleus of IFM cells ofDM2-106 flies. No foci were
Fig. 1. A Drosophila DM2 model forms nuclear CCUG foci. (A) Schematic (not to scale) of the noncoding CCTG repeat constructs used in this study. The
control contains (CCTG)16 repeats (N-16), which is non-toxic in humans. The mutant construct contains (CCTG)106 repeats (DM2-106). Both constructs are
preceded by polymorphic (TG)n(TCTG)n repeats, as indicated, that are also part of the complex human repeat motif. These constructs are under control of the
UAS promotor. (B) In situ hybridization using a locked nucleic acid (LNA) probewas performed on 15 μmcryosections of thoracicmuscles of flies expressingDM2-
106 and control repeats using the myosinMhc-Gal4 driver. DM2-106 expression is associated with the presence of ribonuclear foci (red) in DAPI-stained nuclei
(blue), whereas no foci are detected in controls using the same Gal4 driver. Two representative foci are indicated (arrows). (C) Quantification of nuclei with
ribonuclear foci in control and DM2-106 muscle cells using Mhc-Gal4. Error bars indicate s.d.
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detected in control IFM, whereasmore than 50% of the cells analyzed
had nuclear foci inDM2-106 flies (Fig. 1B,C), demonstrating that 106
CCUG repeats are sufficient to cause biochemical changes. The
average fraction of nuclei with ribonuclear foci in DM2-106 muscle
cells is similar to that observed in a DM1 fly model expressing 480
CTG repeats (García-Alcover et al., 2014).
Expression of DM2-106 in Drosophilamuscles causes mis-
splicing
In order to evaluate DM2-106 flies as a suitable DM2 model, we
examined mis-splicing events in transgenic flies expressing the 106
CCUG repeats in IFM. We studied alternative splicing of the
endogenous Fhos gene (Fig. 2A), which showed aberrant splicing
regulation in DM1 flies expressing a (CTG)480 tract (Garcia-Lopez
et al., 2008) (see also Fig. 2B). For this analysis, we used two
different transgenes for control and DM2-106 constructs, located on
chromosomes 2 and 3. Expression of both DM2-106 transgenes
increased the frequency at which exon 24 was aberrantly included
(Fig. 2B): quantification revealed an increase from ∼30% in N-16
control flies to >70% in DM2-106 flies (Fig. 2C), similar to DM1.
The MBNL proteins are sequestered in (CCUG)DM2 foci and
have been implicated as important mediators of DM2-associated
Fig. 2. DM2-106 expression in muscle causes mis-splicing of MBNL1-dependent transcripts. (A) Outline of the intron/exon structure of Fhos (CG42610)
showing the exons implicated in the splicing event studied. Wild-type flies mainly skipped exon 24 (solid line), whereas DM2-106 expression in IFM led to
aberrant inclusion of exon 24 (dotted lines). Arrows indicate primers used for semi-quantitative PCR analysis. (B,C) Agarose gel and quantification of Fhos
RT-PCR products from IFM expressing control (N-16) and DM2-106 transgenes located on chromosomes 2 and 3. These transgenes were driven byMhc-Gal4.
Flies that only contain the Mhc-Gal4 driver without a UAS transgene show an average frequency of exon 24 inclusion of ∼30%. Compared with this control,
expression of normal repeat length (CCUG)16 does not significantly alter Fhos splicing, whereas in the (CCUG)106 repeat-expressing cells exon 24 is
retained at ∼70%, levels similar to those of DM1 flies expressing an interrupted 480 CUG repeat sequence (iCUG)480. (D,E) Agarose gel and quantification of
Fhos RT-PCR products from flies expressing the indicated transgenes with the Mhc-Gal4 driver. Simultaneous expression of human MBNL1 and DM2-106
induces exon 24 exclusion, restoring wild-type levels (Mhc-Gal4 only). Error bars represent s.d. and each experiment was repeated at least twice in adults of
0-5 days of age. (F-H) Luminescence levels of Mhc-Gal4>UAS-minigene,DM2-106 normalized to the levels of Mhc-Gal4>UAS-minigene,UAS-GFP. Relative
luminescence decreased from 100% in control flies to 78% for the human INSR reporter minigene (F), 38% for TNNT2 (cTNT) (G) and 68% for mouse Tnnt3 (H).
RLU, relative light units. **P<0.005, ***P<0.001 (Student’s t-test). (F′) RT-PCR analysis of the INSR spliceosensor in N-16 and DM2-106 background. The
percentage is the average of two experiments.
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spliceopathy. To validate an involvement of MBNL factors in DM2
flies, we co-expressed the human MBNL1 gene and DM2-106 in
Drosophila IFM. As shown in Fig. 2D, MBNL1 expression rescued
exon 24 inclusion levels in IFM in the presence of (CCUG)106, unlike
GFP protein, whichwas used as a negative control in this co-expression
experiment. The frequency of disease-linked exon 24 inclusion was
reduced from 73% (DM2-106+GFP) to 48% (DM2-106+MBNL1),
close to control levels in the non-disease situation (38%) (Fig. 2E).
The suitability of ourDrosophilaDM2 system as a disease model
was further demonstrated by the observation that different
spliceosensor luciferase reporters, which express specific mammalian
reporter mini-genes for identified mis-splicing events in DM1 and
DM2 (human INSR exon 11 and mouse Tnnt3 fetal exon) (Savkur
et al., 2004; Vihola et al., 2010; García-Alcover et al., 2014), were
also responsive to the presence of expandedCCUG repeats (Fig. 2F,H).
In addition, we tested a TNNT2 exon 5 spliceosensor reporter that
shows mis-splicing in DM1 (Philips et al., 1998). All three
spliceosensor reporters revealed alternative splicing aberrations,
resulting in reduced luciferase luminescence, when (CCUG)106
repeats were expressed in the IFM (Fig. 2F-H). To verify that
the significant changes in luciferase luminescence were due to
mis-splicing, we examined the splicing pattern of the INSR
spliceosensor reporter directly by RT-PCR in our DM2 fly model.
In the Drosophila DM1 model, two splice isoforms of the INSR
spliceosensor were detectable due to the inclusion (isoform B) or
exclusion (isoformA) of an alternative exon between exons 11 and 12
(García-Alcover et al., 2014). Isoform A is preferentially observed in
the disease state (García-Alcover et al., 2014). In the N-16 controls
expressing (CCUG)16, isoform A was present at 42.5% (Fig. 2F′),
consistent with the previous report by García-Alcover et al. (2014).
By contrast, in the presence of expanded (CCUG)106 repeats (DM2-
106), the relative amount of isoform A increased to 65% (Fig. 2F′),
which correlated with the decreased luciferase luminescence
observed in Fig. 2F. These results demonstrated that DM2-106
transgenic flies display a spliceopathy phenotype similar to that seen
in human DM2 patients and thus validate it as a suitable DM2model.
Expression of (CCUG)106 in Drosophila IFM does not cause
muscle atrophy
To study the extent of (CCUG)DM2 toxicity in our DM2 model, we
analyzed IFM samples expressing control or expanded (CCUG)n
(N-16 or DM2-106) for morphological defects similar to those
described in patients (Vihola et al., 2003; Bassez et al., 2008).
However, in contrast to the phenotypic alterations of the IFM in
DM1 models (Fig. 3C), no significant differences were observed
between the IFMs of control and expanded (CCUG)n-expressing
flies (Fig. 3A,B, quantified in Fig. 3D). DM2-106 flies appeared
to be able to fly normally and even aged flies (40 days) did not
display any obvious flight defects. These results demonstrated that
although (CCUG)106 repeats are sufficient to cause biochemical
abnormalities, they are not sufficient to cause morphological and
behavioral phenotypes in the IFM.
Expanded (CCUG)106 repeats cause severe disorganization
of eyemorphology, which ismodified by loss or gain of MBNL
proteins
Because (CCUG)106-expressing flies did not show significant
phenotypic alterations in the IFM, we turned our focus to a different
phenotype commonly observed in DM2 pathogenesis, namely
ocular manifestations. For that purpose, we expressed control (N-
16) and DM2-106 transgenes using GMR-Gal4 in the posterior half
of developing eye imaginal discs, which form the retina during late
larval and pupal stages. Adult flies expressing the (CCUG)106
transgenes developed eyes of severely disorganized morphology
(Fig. 4C). By contrast, control GMR-Gal4>N-16 flies displayed
only mildly rough eyes, as compared with GMR-Gal4-only eyes
(Fig. 4A,B). Both transgenes are expressed at similar levels
(Fig. 4H). Thus, in contrast to the IFM, expression of expanded
(CCUG)106 repeats caused severe phenotypic abnormalities in the
fly eye. A similar observation has recently been reported for a
different DM2 fly model (Yu et al., 2015).
As described above,MBNL proteins are thought to be involved in
DM2 pathogenesis. To confirm this in our DM2 fly model, we
examined whether alterations to the gene dose of Drosophila mbl
would modify the DM2-106 phenotype. In a heterozygous mbl+/−
background, the eye phenotype of adult DM2-106 flies is severely
enhanced (Fig. 4E). The eyes are rougher and more disorganized,
and often also reduced in size. Phenotypic rescue is observed when
the human MBNL1 protein is overexpressed in DM2-106 flies,
which suppressed the DM2-106 eye phenotype (Fig. 4F). The eyes
appear almost normal and ommatidial integrity is visible.
Expression of a control UAS transgene, UAS-GFP, does not
Fig. 3.DM2-106expressiondoesnot causemorphological defects inDrosophilamusculature. (A-C) IFM transverse sections fromcontrol flies (Mhc-Gal4/+)
or flies expressing either (CCUG)106 (DM2-106) or (CUG)480 (DM1). (CUG)480 expression leads to vacuolization andmuscle disorganization (Garcia-Lopez et al.,
2008), whereas (CCUG)106 expression was not disruptive to muscle fiber morphology. (D) Relative muscle areas of at least six independent thoraces of each
genotype were calculated after binarization using ImageJ and statistically analyzed using a two-tailed, non-paired t-test (P=0.118). Error bars indicate s.d.
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affect the DM2-106 eye phenotype (Fig. 4D), suggesting that the
rescue by MBNL1 expression is not due to the additional UAS
transgene. Immunolocalization reveals that MBNL1 protein is
localized in CCUG foci (Fig. 4I-I″, arrows), but we also observe
aggregates of MBNL1 protein outside of CCUG foci (Fig. 4I,I″,
arrowheads).
Another protein implicated in the pathology of DM1 is CUGBP1
(Timchenko et al., 2001a,b; de Haro et al., 2006; Jones et al., 2011;
Timchenko, 2013). However, in contrast to MBNL1, expression of
human CUGBP1 has little or no effect on the morphology of DM2-
106 eyes (compare Fig. 4G with 4C).
DM2-106 causes severe disruption of retinal organization
To further characterize the eye phenotype of GMR>DM2-106 flies,
we examined the underlying retinal morphology. The developing
retina is fully differentiated at 42 h after puparium formation
(APF). In wild-type retinae at that stage, photoreceptor neurons,
cone cells and pigment cells are highly organized in a stereotypical
pattern to form the individual ommatidia. Each ommatidium
contains four concentrically aligned cone cells surrounded by
pigment cells (Fig. 5A″). In GMR-Gal4>N-16 control flies, this
pattern is not significantly disturbed (Fig. 5A-A″). By contrast, in
GMR>DM2-106 retinae the precise cellular arrangement is
severely disrupted, with photoreceptor neurons, cone cells and
pigment cells irregularly positioned and numbered (Fig. 5B-B″).
Ommatidia were fused and ommatidial identity was not observed.
Thus, expression of (CCUG)106 RNA caused severe disruption of
retinal morphology.
Apoptosis induced byDM2-106 causes retinal disruption and
disorganization
Recently, apoptosis has been implicated in muscle degeneration in a
Drosophila DM1 model (Bargiela et al., 2015). Therefore, we
examined whether apoptosis contributes to the retinal phenotype in
GMR>DM2-106 transgenic flies. In GMR-Gal4>N-16 control flies,
no or very little apoptosis occurs in eye imaginal discs, the larval
precursors of the adult eyes (Fig. 6A). However, inGMR>DM2-106
eye imaginal discs, apoptosis is strongly induced in the GMR
domain in the posterior half of the larval disc (Fig. 6B, arrow),
suggesting that (CCUG)106 RNA triggers apoptosis. P35 is a potent
inhibitor of apoptosis, and specifically inhibits effector caspases in
flies (Hay et al., 1994; Hawkins et al., 2000; Meier et al., 2000). Co-
expression of p35 together withDM2-106 underGMR-Gal4 control
suppressed the apoptotic phenotype in larval eye imaginal discs
(Fig. 6C). Because P35 potently suppressed apoptosis in DM2-106
flies, wewere able to dissect the relative contribution of apoptosis to
Fig. 4. Expression of expanded
(CCUG)n causes severe disruption of
eye morphology, which can be
modified by loss or gain of MBNL.
(A) The eye of a GMR-Gal4-only fly.
(B) Expression of the control N-16
transgene under the GMR-Gal4 driver
shows a very mild eye roughening, which
is caused by GMR-Gal4. (C) Disruption of
the external eye morphology of a fly that
expressesDM2-106 usingGMR-Gal4. (D)
Expression of a UAS control transgene,
UAS-GFP, does not rescue the eye
phenotype of GMR-Gal4>DM2-106 flies.
(E) Heterozygosity for a null allele of
muscleblind (mblKG08885), resulting in
functional hemizygosity, severely
enhances the DM2-106 eye phenotype
owing to the 50% reduction in MBL protein
levels. (F) Expression of human MBNL1
rescues the eye phenotype of DM2-106
flies under GMR-Gal4 control. (G) Co-
expression of a CUGBP1 transgene using
GMR-Gal4 does not rescue or provides
only very little rescue of the external eye
morphology of DM2-106 flies. (H)
Expression levels of control (N-16) and
experimental (DM2-106) transgenes
under GMR-Gal4 control in eye imaginal
discs. Statistical analysis was by two-
tailed, non-paired t-test (P=0.222).
(I-I″) MBNL1 protein (green) accumulates
in CCUG foci (red) in GMR-Gal4>DM2-
106 eye imaginal discs (arrows).
Interestingly, MBNL1 also aggregates in
foci independently of CCUG repeats
(arrowheads). Nuclei are labeled with
DAPI (blue).
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the DM2-106 retinal and eye morphology phenotypes. Co-
expression of p35 in the DM2-106 model normalized the external
eye morphology of adult flies (Fig. 6D, compare with Fig. 4C).
Furthermore, co-expression of p35 suppressed the misalignment of
photoreceptor neurons and cone cells, restoring ommatidial
integrity (Fig. 6E,F, compare with Fig. 5B). These data illustrate
that expression of the DM2-106 transcript caused apoptosis that
resulted in retinal disruption and disorganization.
Feasibility of the DM2-106model for chemical screening
The data presented here suggest that expression of DM2-106 in the
Drosophila retina mimics pathological manifestations seen in the
human condition, including the formation of toxic CCUG foci, as
well as retinal disorganization and degeneration. Therefore, DM2-
106 might provide a suitable and convenient model for drug
screening and identification of lead compounds (García-Alcover
et al., 2013). To assess the feasibility of our DM2-106 model for
drug screening, we tested two compounds that have previously been
shown to have therapeutic potential in DM1 models. Pentamidine is
a dsRNA-intercalating drug that was found to disrupt the MBNL1-
CUG repeat complex in DM1 (Warf et al., 2009). It was recently
reported that pentamidine treatment can also rescue cardiac
dysfunction in a Drosophila DM1 model (Chakraborty et al.,
2015). The second drug, the oxindole/imidazole derivative C16, is
an inhibitor of the dsRNA-dependent protein kinase PKR (PKR-I),
which is activated by expanded CUG repeats in DM1 (Tian et al.,
2000, 2005; Huichalaf et al., 2010; Wojciechowska et al., 2014). As
an assay for drug treatment, we examined the ability of the selected
inhibitors to block the formation of toxic CCUG foci in the DM2-
106-expressing retina (Fig. 7B). Interestingly, these foci were not
only nuclear, but could also be observed in the cytoplasm (Fig. 7B,
arrows). Pentamidine treatment up to 350 μM, a concentration that
has been shown to be effective in DM1 (Warf et al., 2009), has no
visible effect on RNA foci formation in the DM2-106 model
(Fig. 7C-E). By contrast, treatment with PKR-I showed a pronounced
decrease in the abundance of CCUG RNA foci in a concentration-
dependent manner: 4 μM PKR-I caused a significant reduction of
RNA foci, and 7 μM completely disrupted foci formation (Fig. 7F-
H), resembling wild-type retinae (Fig. 7A). Consistently, loss of
CCUG foci by PKR-I treatment correlated with reduction and loss of
apoptosis (Fig. 7I-L). These examples illustrate that the DM2-106
retina might provide a convenient model for drug screening in flies.
The suppression of foci formation and apoptosis by PKR-I
suggests that PKR activity is increased in the retinae of DM2-106
expressing pathogenic CCUG repeats. Activation of PKR by
expanded CUG repeats in DM1 has been reported (Tian et al., 2000;
Fig. 5. DM2-106 causes severe disruption of retinal morphology. Fully
differentiated retinae of pupal eye imaginal discs at 42 h APF labeled with
antibodies against ELAV (a marker for photoreceptor neurons; A,B), Cut (a
marker of cone cells; A′,A″,B′,B″) and Dlg (to visualize cell outline and thus
reveal pigment cells; A′,B′). (A′,B′) Double labeling for Cut and Dlg.
(A-A″)GMR>N-16 control retina showing the regular pattern of photoreceptors
(A), cone (A′,A″) and pigment cells (A′). (B-B″) Retina expressing DM2-106
under GMR-Gal4 control shows irregularities of photoreceptor neurons
(B), cone and pigment cells (B′,B″).
Fig. 6. Induction of apoptosis results in disruption
of the photoreceptor neuron pattern in DM2-106
retinae. (A-C) TUNEL labeling as a marker for
apoptosis of N-16 (A), DM2-106 (B) and DM2-106+p35
(C) eye imaginal discs from third instar larvae under
GMR-Gal4 control. The extent of the GMR expression
domain in the larval eye disc is indicated. The arrow (B)
highlights the induced apoptosis in the posterior part of
the larval eye disc where GMR-Gal4 is expressed.
(D) Rescue of the external eye morphology of adult
DM2-106 flies expressing the caspase inhibitor p35
under GMR-Gal4 control. (E,F) GMR>DM2-106+p35
pupal retinae at 42 h APF labeled for the
photoreceptor marker ELAV (E) and the cone cell
marker Cut (F). Inhibition of apoptosis by co-expression
of the caspase inhibitor P35 normalizes the
photoreceptor and cone cell pattern in GMR>DM2-106
retinae (compare with Fig. 5B).
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Huichalaf et al., 2010; Wojciechowska et al., 2014). It is currently
unknown whether PKR is also activated in DM2. To examine this
possibility, we tested a known PKR phosphorylation target,
eukaryotic translation initiation factor 2 alpha (eIF2α) (Proud,
2005). In humans, PKR phosphorylates and inactivates eIF2α on
Ser51 (Proud, 2005). This phosphorylation site is conserved in
Drosophila eIF2α, and phospho-specific eIF2α (P-Ser51)
antibodies cross-react with phosphorylated Drosophila eIF2α
(Williams et al., 2001; Farny et al., 2009). These antibodies detect
a strong increase in eIF2α phosphorylation on Ser51 in DM2-106
retinae as compared with the N-16 control (Fig. 8A-C). Importantly,
this strong increase in Ser51 phosphorylation in DM2-106 retinae
was significantly reduced upon dietary administration of 7 μM
PKR-I (Fig. 8D). These data suggest that PKR activity is strongly
induced in the presence of 106 CCUG repeats in the retina.
DISCUSSION
The goal of this work was to develop a fly model that can be used for
drug screening to identify therapeutic compounds for potential
treatment of DM2 patients. The rationale was that many cell
biological processes, including apoptosis, alternative RNA splicing
and the genes/proteins involved, are highly conserved between flies
and humans. Furthermore, the genetic tools available in Drosophila
allow for rapid characterization of the underlying phenotypes.
Finally, experimentation with flies is relatively inexpensive and the
short generation time enables rapid genetic and chemical screening.
Here, we describe a DM2 fly model that expresses 106 CCUG
repeats in a non-coding transcript (DM2-106). Several features of
DM2-106 flies indicate that expression of expanded (CCUG)106
RNA elicits molecular and cellular phenotypes similar to those
associated with DM2 pathology in human patients. DM2-106
transcripts aggregate in RNA foci that are predominantly nuclear,
but can also be observed in the cytoplasm, at least in retinal cells.
Cytoplasmic (CCUG)DM2 foci have also recently been described in
human HeLa cells (Jones et al., 2015). These RNA foci sequester
MBNL proteins, which causes mis-splicing in muscles similar to that
seen in human DM2 patients. Although we did not observe muscle
atrophy in DM2-106 flies, the retinae and eyes of these flies were
severely disrupted. Functional complementation byoverexpression of
human MBNL1 protein in GMR>DM2-106 rescued the retinal
degeneration. Furthermore, inhibition of apoptosis restored the retinal
pattern and eye morphology, suggesting that expression of
(CCUG)106 in DM2-106 flies induced apoptosis as the underlying
cause of the retinal degeneration. The involvement of apoptosis in
retinal degeneration is consistent with the recent finding that
apoptosis also contributes to muscle degeneration in a Drosophila
DM1 model (Bargiela et al., 2015). In a pilot drug screening
experiment in DM2-106 eyes, we found that an inhibitor of PKR
activity efficiently blocked formation of RNA foci and apoptosis,
whereas pentamidine failed to inhibit foci formation. Finally, we
show that pathogenic (CCUG)n DM2 repeat expansions activate the
dsRNA-dependent protein kinase PKR, similar to previous reports in
DM1 (Tian et al., 2000; Huichalaf et al., 2010; Wojciechowska et al.,
2014). Taken together, these data suggest that our DM2-106 fly
model provides a convenient tool for drug screening.
While this work was under way, another group published a
different DM2model inDrosophila (Yu et al., 2015). These authors
were able to express more than 700 CCUG repeats in flies.
Consistent with our observations, expression of (CCUG)700 repeats
caused retinal and eye disruption. Interestingly, muscle atrophy was
also not reported (Yu et al., 2015), suggesting that inDrosophila the
eye is perhaps more sensitive to RNA perturbations than skeletal
muscle. In this context, it is worth noting that muscle weakness and
atrophy are generally weaker in DM2 patients than in DM1 (Udd
and Krahe, 2012). Alternatively, it is possible that there is an
expansion threshold that underlies tissue-specific manifestations of
the overall DM2 phenotype and that the expression of (CCUG)106
repeats is insufficient in itself to induce muscle phenotypes due to
mis-splicing, but could involve the recently identified RAN (repeat-
associated non-ATG) translation as another pathomechanism (Zu
et al., 2011).
Despite the fact that DM1 and DM2 share many pathological
manifestations, they are not identical diseases (Udd and Krahe,
Fig. 7. Treatment with PKR inhibitor, but not pentamidine, blocks foci
formation and apoptosis in DM2-106 retinae. (A-H) Shown are 42 h APF
retinae from control (A), untreated GMR>DM2-106 (B) and GMR>DM2-106
treated with various buffers and drugs (C-H) as indicated. These retinae were
labeled for CCUG foci (red) and nuclei (blue). Arrows indicate example foci,
both nuclear and cytoplasmic. Whereas pentamidine treatment did not block
foci formation up to a concentration of 350 μM, treatment with PKR inhibitor
(oxindole/imidazole derivative C16, PKR-I) suppressed foci formation in a
concentration-dependent manner. (I-L) Eye imaginal discs from control (I),
untreated GMR>DM2-106 (J) and GMR>DM2-106 treated with the indicated
concentrations of PKR-I (K,L). Eye discs were obtained from third instar larvae
andwere labeled by TUNEL as an apoptotic marker. Arrows indicate apoptosis
in the GMR-expression area.
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2012). For example, they affect different types of muscle and the
neurological symptoms in DM2 are generally less severe (Thornton,
2014; Ulane et al., 2014). We also observed differences between the
DM1 and DM2 models in Drosophila. Whereas expression of
CUGBP1 enhanced the DM1 phenotype (de Haro et al., 2006), it
had no obvious effect on the eye phenotype of GMR>DM2-106
flies. Furthermore, pentamidine treatment, which was shown to be
effective in DM1 (Chakraborty et al., 2015), had no effect on foci
formation in DM2-106. Therefore, comparative analysis of DM1
and DM2 fly models might reveal additional differences that
underlie the two diseases and thereby provide important insights
into the etiology of the human phenotypes.
Our pilot drug screen revealed that the DM2-106 Drosophila
model is well suited for drug screening. Treatment ofDM2-106 flies
with increasing concentrations of a PKR inhibitor disrupted CCUG
RNA foci formation and apoptosis in eye imaginal discs, the larval
precursor tissue of adult retinae and eyes. PKR encodes a dsRNA-
dependent protein kinase, which was found to be activated in DM1.
Our data suggest that PKR activity is also induced by expanded
(CCUG)n DM2 repeats. Unfortunately, although PKR-I feeding of
larvae disrupted CCUG foci formation in GMR>DM2-106 eye
imaginal discs, the resulting eye phenotype of adult flies was not
rescued (Fig. S1). A possible explanation for this observation is that
flies stop feeding after the larval stage, so that during pupal stages
the eye phenotype can still develop. Nevertheless, we are confident
that modeling of DM2 in Drosophila will further contribute to our
understanding of the pathology of DM2 and provide an excellent
platform for genetic and chemical (drug) screening.
MATERIALS AND METHODS
Generation of control and expanded (CCUG)n repeat expression
clones
The (CCTG)DM2 expansion is part of a complex polymorphic motif
(Bachinski et al., 2003, 2009) of the form (TG)12-26(TCTG)7-12(CCTG)3-
9(G/TCTG)0-4(CCTG)4-15. DM2 expansions can be as large as 40 kb with
the CCTG motif uninterrupted (Liquori et al., 2001; Bachinski et al., 2003;
Sallinen et al., 2004). Reported normal alleles have repeat tract lengths of up
to 26 CCTG motifs with one or more interruptions (Bachinski et al., 2009).
The smallest reported DM2 expansions associated with clinically detectable
manifestations are between 55 and 100 CCTG repeats (Liquori et al., 2001;
Lucchiari et al., 2008; Bachinski et al., 2009). Because this complex
polymorphic repeat motif has been shown to have an effect on DNA
structure (Edwards et al., 2009), we included the (TG)n(TCTG)n tracts in the
(CCTG)DM2 constructs. We took advantage of the repeat-primed PCR (RP-
PCR) assay developed in our laboratory (R.K.) for the diagnostic detection
of the DM2 expansions (Sallinen et al., 2004; Bachinski et al., 2009). Using
this approach, we amplified repeats from a clinically affected, genetically
confirmed DM2 patient to produce (TG)n(TCTG)n(CCTG)n repeats with 16
to 189 pure (CCTG)n motifs. Cloned repeats were verified by sequencing to
ensure purity of the expanded (CCTG)n repeat tract. In order to express the
(CCTG)n repeats in Drosophila, mutant fragments containing 106 repeats
with the upstream region were recovered from the TOPO vector and cloned
into pUAST (Brand and Perrimon, 1993). The same cloning procedure was
used with genomic DNA from a normal individual to generate the control
vector containing a normal (CCTG)16 allele. The presence and the length of
the (CCTG)n repeats in the pUAST vector were confirmed by sequencing in
both directions: DM2-106, (TG)22(TCTG)2(CCTG)106; and N-16,
(TG)20(TCTG)12(CCTG)16.
Generation of the MBNL1 expression clone
The human MBNL1 clone was obtained from OriGene (TrueClone
accession number NM_021038.3). The plasmid was digested with NotI,
to separate the insert from the vector, and with SpeI, to decrease the vector
size and distinguish it from the insert. The NotI insert with the entire coding
sequence for MBNL1 was then cloned into the NotI site of the pUAST
vector. Proper orientation was confirmed by restriction enzyme digestion
and sequence analysis from both ends.
Generation of the CUGBP1 expression clone
The human CUGBP1 clone was obtained from OriGene (TrueClone
accession number NM_006560.2). This variant is the predominant
transcript and encodes isoform 1. To generate the expression clone, we
used the same procedure as for the MBNL1 expression clone, except for the
SpeI digestion, since insert and vector were readily distinguishable by size in
gel electrophoresis.
Fly husbandry
Flies were raised on normal corn agar and crosses were incubated at 25°C.
The following mutants and transgenic stocks were used: UAS-[CCTG]16
(control); UAS-[CCTG]106 (DM2-106); UAS-MBNL1; UAS-CUGBP1;
UAS-p35; Mhc-Gal4; GMR-Gal4; mblKG08885. Generation and
management of DM1 spliceosensor flies was as described (García-
Alcover et al., 2014). To simplify crosses, DM2-106 transgenes on
chromosome 2 or 3 were recombined with GMR-Gal4 on the same
chromosome to yieldGMR>DM2-106 on chromosome 2 or 3. Fly eyes were
photographed using a Zeiss Axio Imager Z1 compound microscope.
Drug treatment
Fly food was supplemented with drugs at the final concentrations indicated
in Figs 7, 8 and Fig. S1. Pentamidine was obtained from Sigma-Aldrich
(439843) and PKR-I from Calbiochem (527451). Because PKR-I needs to
be dissolved in 100% DMSO, a DMSO-only control was also performed.
The same volume of DMSO-containing solutions was mixed into the food.
Reverse transcription PCR (RT-PCR) analysis
For Fhos and INSR splicing assays, total RNAwas extracted from ∼50 adult
flies with Tri Reagent (Sigma) following the manufacturer’s instructions.
Contaminating DNA was degraded by RNase-free DNase I (Thermo
Scientific). Reverse transcription was performed with SuperScript II reverse
transcriptase (Invitrogen) following the manufacturer’s guidelines. GoTaq
polymerase (Promega) was used for PCR amplification with primers (5′-3′)
Fhos-F (GTCATGGAGTCGAGCAGTGA) and Fhos-R (TGTGATGCG-
GGTATCTACGA), or with primers INSR-F (ACGTTTGAGGATTACC-
TGCACAA) and INSR-R (GAGATGGCCTGGAACGACAG), in each
case for 29 cycles, with an annealing temperature of 60°C (García-Alcover
et al., 2014). Band intensity was quantified using ImageJ (NIH).
For quantification of N-16 and DM2-106 transcript levels (Fig. 4H), total
RNA was extracted from Drosophila eye imaginal discs using TRIzol rea-
gent (Invitrogen). cDNA conversion was performed using the SuperScript II
RNase H-Reverse Transcriptase Kit (Invitrogen). Quantitative PCR (qPCR)
was performed using cDNA template and SYBRGreen PowerMix (Applied
Fig. 8. Expression of pathogenic (CCUG)106 increases
PKR activity in retinae of GMR>DM2-106 flies. The
posterior portions of eye imaginal discs from third instar larvae
of the indicated genotype labeled with phospho-specific eIF2α
(P-Ser51) antibody to detect PKR activity. GMR-Gal4>UAS-
N-16 (A,B) or GMR-Gal4>UAS-DM2-106 (C,D) discs were
treated (B,D) or not (A,C) with 7 μM PKR-I.
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Biosystems). Three sets of primers flanking the CCUG repeats were desi-
gned in the pUAST vector used to clone the transgenes: primer set #1, Fwd
GTGGTGGAATGCCTTTAAT and Rev GGAGGAGTAGAATGTTGA-
GA; primer set #2, Fwd AAAGAAGAGAAAGGTAGAAGAC and Rev
AGCAAAGCAAGCAAGAG; primer set #3, Fwd CTAGTGATGATGA-
TGAGGCTACT and Rev TAGCAATTCTGAAGGAAAGTC. Transcript
levels of Ribosomal protein 49 (Rp49; also known as RpL32) were used for
normalization across samples, using primers Fwd ACCAGCTTCAAGAT-
GACCATCC and Rev CTTGTTCGATCCGTAACCGATG.
Fluorescence in situ hybridization (FISH)
FISH analysis was performed as described (Salisbury et al., 2009), except
that Drosophila tissue was used. Imaginal discs were imaged by confocal
microscopy. RNA-FISH analysis of drug-treated retinaewas performed with
a (CUGG)10 probe.
For muscle preparation, thoraces of 0- to 5-day-old MHC-Gal4>UAS-
(CCTG)106 or MHC-Gal4>UAS-(CCTG)16 females were dissected,
embedded in OCT (Fisher HealthCare), frozen in liquid nitrogen and
stored at −80°C until processed. At least five 40× magnification images of
different focal planes along the z-axis were taken using a Leica DM2500
microscope for DAPI (UV channel) and Cy3 (green channel). The z-planes
were stacked using Photoshop (Adobe) and the number of nuclei with foci
counted with ImageJ software. At least 50 cells from each individual were
counted and at least three individuals were analyzed for each compound.
The percentage of cells with foci was compared betweenMHC-Gal4>UAS-
(CCTG)106 and MHC-Gal4>UAS-(CCTG)16.
Luciferase readout
Three 0- to 5-day-old adult flies were placed in each well of a flat-bottom
96-well plate (Daslab, Barcelona, Spain) and homogenized in 150 μl 1×
reporter lysis buffer (Promega). Then, 50 μl of the homogenate was
transferred to a new white 96-well plate (Sterilin). Lysate luminescence was
measured with an Envision plate reader (PerkinElmer) after dispensing 15 μl
Luciferase Assay Reagent (Promega) with the Envision injector. At least 60
wells were analyzed for each genotype studied.
Muscle histology
Drosophila thoraces (7-12 days old) were embedded in Epon for semi-thin
transverse sectioning as previously described (Tomlinson and Ready, 1987).
Relative muscle areas of at least six different thoraces were calculated as
described (Garcia-Lopez et al., 2011).
Immunohistochemistry
At least 20 imaginal discs per experiment were dissected from late third instar
larvae and pupal retinae from 42-h-old pupae. They were fixed and stained
using standard protocols (Fogarty and Bergmann, 2014). TUNEL was
performed using a TUNEL assay kit (Roche Life Sciences) according to the
manufacturer’s instructions. Antibodies to the following primary antigens
were used: ELAV [rat; 1:50; Developmental Studies Hybridoma Bank
(DSHB)]; Cut (mouse; 1:50; DSHB); Dlg (rabbit; 1:100; from Kwang-Wook
Choi, Korea Advanced Institute of Science and Technology, Daejeon, South
Korea); MBNL1 (rabbit; 1:2000; from Charles Thornton, University of
Rochester Medical Center, Rochester, NY, USA); cleaved Caspase 3 (rabbit;
1:200; Cell Signaling Technology, 9661); and eIF2α (P-Ser51) (rabbit; 1:100;
Cell Signaling Technology, 3597). Secondary antibodies were donkey Fab
fragments from Jackson ImmunoResearch (715-166-151, 711-096-152, 712-
606-153, 711-166-152; all at 1:600). Nuclei were visualized by Hoechst and
DAPI staining. Fluorescent images were taken with an Olympus Optical
FV500 confocal microscope.
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